This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
pancreatic-cancer
Pancreatic Cancer
Aggressive exocrine malignancy; KRAS mutations in >90%, TP53 in ~75%, CDKN2A and SMAD4 in ~50%; desmoplastic stroma limits drug delivery. FOLFIRINOX and gemcitabine+nab-paclitaxel are standards; KRAS inhibitors (sotorasib for G12C) and BRCA-mutant PARP inhibitors are active.
Entry Metadata
| Field | Value |
|---|---|
| ID | pancreatic-cancer |
| Name | Pancreatic Cancer |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825. · PubMed 21561347
- Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317-327. · PubMed 31157963
- Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703. · PubMed 24131140